This trial aims to evaluate the effectiveness of treating patients with heart disease using bone marrow stem cells administered directly into the muscle of left ventricle. The trial is being conducted at the Silesian Medical University in Katowice. To be part of the study, participants will have angina which does not respond to standard drug treatment and myocardial ischemia without possibility of effective revascularization. Participants will be randomly divided into two groups. One group will receive their own bone marrow stem cells (CD133+) directly into the heart muscle (experimental group). The other group will receive only a placebo injection (control group). Participants will be monitored for complications and changes in their clinical condition. The trial commenced in June 2012 and expects to enrol 60 patients.